THB335 Program Next Steps (GlobeNewswire) - Feb 11, 2025 - "The Company intends to continue THB335 development activities through the first half of 2025 to prepare for the initiation of a 12-week, placebo-controlled Phase 2 study in CSU by mid-year 2025. Key near-term activities include completion of ongoing subchronic toxicology studies and submission of regulatory filings to position THB335 for Phase 2 initiation."
New P2 trial • Chronic Spontaneous Urticaria
|